ABCELLERA BIOLOGICS Total Assets
ABCELLERA BIOLOGICS total assets. Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) holds total assets worth €1.31 Billion EUR (≈ $1.53 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 8QQ company net worth for the company's overall valuation and market capitalisation.
Total Assets of ABCELLERA BIOLOGICS (2021–2025)
Total assets of ABCELLERA BIOLOGICS from 2021 to 2025. This chart illustrates how ABCELLERA BIOLOGICS's total assets have evolved over time, based on quarterly financial data. See 8QQ stock price for real-time trading data and today's change.
ABCELLERA BIOLOGICS - Asset Composition Analysis
ABCELLERA BIOLOGICS Total Assets Breakdown (December 2025)
ABCELLERA BIOLOGICS total assets breakdown as of December 2025. ABCELLERA BIOLOGICS's total assets of €1.31 Billion consist of 53.7% current assets and 46.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.5% |
| Accounts Receivable | €58.29 Million | 4.3% |
| Inventory | €6.34 Million | 0.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €38.38 Million | 2.8% |
| Goodwill | €47.81 Million | 3.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 8QQ working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABCELLERA BIOLOGICS's current assets represent 53.7% of total assets in 2025, a decrease from 70.5% in 2021.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, down from 36.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 14.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 4.3% of total assets.
ABCELLERA BIOLOGICS Competitors by Total Assets
Key competitors of ABCELLERA BIOLOGICS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
ABCELLERA BIOLOGICS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.77 | 11.07 | 9.34 |
| Quick Ratio | 12.63 | 11.07 | 9.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €626.04 Million | €675.12 Million | €663.32 Million |
ABCELLERA BIOLOGICS - Advanced Valuation Insights
This section examines the relationship between ABCELLERA BIOLOGICS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.97 |
| Latest Market Cap to Assets Ratio | 2.32 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | €1.36 Billion |
| Market Capitalization | $3.15 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ABCELLERA BIOLOGICS's assets at a significant premium (2.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: ABCELLERA BIOLOGICS's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual total assets of ABCELLERA BIOLOGICS from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.36 Billion ≈ $1.59 Billion |
-0.26% |
| 2024-12-31 | €1.36 Billion ≈ $1.59 Billion |
-8.57% |
| 2023-12-31 | €1.49 Billion ≈ $1.74 Billion |
-3.43% |
| 2022-12-31 | €1.54 Billion ≈ $1.80 Billion |
+16.86% |
| 2021-12-31 | €1.32 Billion ≈ $1.54 Billion |
-- |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more